Acurx Pharmaceuticals, Inc.
Close on Oct 19, 2026
- Market cap
- $4.86M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q1 FY2025 Ended Mar 31, 2025 | May 13, 2025 | Before market open | – | $-0.11 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 18, 2025 | Before market open | – | $-0.16 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 13, 2024 | Before market open | – | $-0.17 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 9, 2024 | Before market open | – | $-0.26 | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 15, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 18, 2024 | After market close | – | $-0.37 | – |
| Q3 FY2023 Ended Sep 30, 2023 | Nov 14, 2023 | After market close | – | $-0.24 | – |
| Q2 FY2023 Ended Jun 30, 2023 | Aug 14, 2023 | Before market open | – | $-0.28 | – |
| Q4 FY2022 Ended Dec 31, 2022 | Mar 16, 2023 | Before market open | – | – | – |
| Q3 FY2022 Ended Sep 30, 2022 | Nov 14, 2022 | Before market open | – | – | – |
| Q2 FY2022 Ended Jun 30, 2022 | Aug 15, 2022 | After market close | – | – | – |
| Q1 FY2022 Ended Mar 31, 2022 | May 11, 2022 | Before market open | – | – | – |
Press releases
Announcements Acurx Pharmaceuticals filed with the SEC
Acurx Pharmaceuticals, Inc. Announces up to
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Announces New Ibezapolstat Clinical Trial Program in Patients with Recurrent CDI That Has the Potential to Shift the Paradigm
Executive or director change · Other events · EX-99.1 to Form 8-K
Inc. Announces Reverse Stock Split
Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
/C O R R E C T I O N -- Acurx Pharmaceuticals, Inc./ PR Newswire
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Acurx Pharmaceuticals, Inc. Reports First Quarter Results
Results of operations · EX-99.1 to Form 8-K
Inc. Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Inc. Announces $1.1 Million Registered Direct Offering
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Inc. Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Acurx Pharmaceuticals, Inc. Reports Third Quarter
Results of operations · EX-99.1 to Form 8-K
Acurx Pharmaceuticals, Inc. Reports Second Quarter 2024
Results of operations · EX-99.1 to Form 8-K
Acurx Pharmaceuticals, Inc. Reports First Quarter
Results of operations · EX-99.1 to Form 8-K
Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Acurx Pharmaceuticals, Inc. Reports Third Quarter 2023 Results
Results of operations · EX-99.1 to Form 8-K
Top-Line Ibezapolstat Phase 2 Efficacy Results with 96% Clinical Cure Rate in Patients with C. difficile Infection
Other events · EX-99.1 to Form 8-K
Successful Completion and Early Discontinuation of the Ibezapolstat Phase 2b Trial for Treatment of C. difficile Infection
Other events · EX-99.1 to Form 8-K
Acurx Pharmaceuticals, Inc. Reports Second
Results of operations · EX-99.1 to Form 8-K
Acurx Pharmaceuticals, Inc. Reports Fourth Quarter
Results of operations · Other events · EX-99.1 to Form 8-K
Acurx Pharmaceuticals, Inc. Reports Third
Results of operations · EX-99.1 to Form 8-K
Second Quarter 2022 Results and Provides
Results of operations · EX-99.1 to Form 8-K
Acurx Pharmaceuticals, Inc. Announces $4.225
Material agreement · Results of operations · Unregistered share sale · EX-99.1 to Form 8-K
Pharmaceuticals, Inc. Reports First Quarter 2022 Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
am ET on Thursday, March 17, 2022
Results of operations · EX-99.1 to Form 8-K
Pharmaceuticals, Inc. Reports Third Quarter 2021 Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K